Abstract
Clonazepam was initially licensed as an anti-epileptic agent, but its use in a wide variety of psychiatric conditions, including panic disorder (PD) has now been well established. This overview evaluates the current role of clonazepam alone or in combination with antidepressants and/or behavioral therapy in the treatment of PD. We review the data establishing the use of clonazepam in the treatment of PD as well as new information, particularly confirmation of longterm efficacy and safety. We also discuss a regimen for safely tapered withdrawal of clonazepam, the characteristics of the respiratory subtype of PD, and CO2-induced panic attacks as a diagnostic measure and predictor for therapeutic success. It has been shown that panic attacks can more readily be induced by CO2 in PD patients with the respiratory subtype than those with the non-respiratory subtype. More than 25 years after the first report of efficacy in PD in 1984, clonazepam, alone or combined with selective serotonin reuptake inhibitors (SSRIs) and/or behavioral therapy, remains an important therapeutic modality for the management of PD.
Keywords: Behavioral therapy, carbon dioxide test, clinical studies, clonazepam, panic disorder, selective serotonin reuptake inhibitors, tapering, benzodiazepines, SSRIs or, anxiety symptoms
Current Drug Targets
Title:Clonazepam for the Treatment of Panic Disorder
Volume: 14 Issue: 3
Author(s): Antonio E. Nardi, Sergio Machado, Leonardo Ferreira Almada, Flavia Paes, Adriana Cardoso Silva, Ricardo Jose Marques, Roman Amrein, Rafael C. Freire, Rocio Martin-Santos, Fiammeta Cosci, Jaime E. Hallak, Jose A. Crippa and Oscar Arias-Carrion
Affiliation:
Keywords: Behavioral therapy, carbon dioxide test, clinical studies, clonazepam, panic disorder, selective serotonin reuptake inhibitors, tapering, benzodiazepines, SSRIs or, anxiety symptoms
Abstract: Clonazepam was initially licensed as an anti-epileptic agent, but its use in a wide variety of psychiatric conditions, including panic disorder (PD) has now been well established. This overview evaluates the current role of clonazepam alone or in combination with antidepressants and/or behavioral therapy in the treatment of PD. We review the data establishing the use of clonazepam in the treatment of PD as well as new information, particularly confirmation of longterm efficacy and safety. We also discuss a regimen for safely tapered withdrawal of clonazepam, the characteristics of the respiratory subtype of PD, and CO2-induced panic attacks as a diagnostic measure and predictor for therapeutic success. It has been shown that panic attacks can more readily be induced by CO2 in PD patients with the respiratory subtype than those with the non-respiratory subtype. More than 25 years after the first report of efficacy in PD in 1984, clonazepam, alone or combined with selective serotonin reuptake inhibitors (SSRIs) and/or behavioral therapy, remains an important therapeutic modality for the management of PD.
Export Options
About this article
Cite this article as:
E. Nardi Antonio, Machado Sergio, Ferreira Almada Leonardo, Paes Flavia, Cardoso Silva Adriana, Jose Marques Ricardo, Amrein Roman, C. Freire Rafael, Martin-Santos Rocio, Cosci Fiammeta, E. Hallak Jaime, A. Crippa Jose and Arias-Carrion Oscar, Clonazepam for the Treatment of Panic Disorder, Current Drug Targets 2013; 14 (3) . https://dx.doi.org/10.2174/1389450111314030007
DOI https://dx.doi.org/10.2174/1389450111314030007 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers